The effects of a new beta-adrenergic stimulator (saligenin, AH3365) on the general and coronary haemodynamics and metabolism of the intact dog.
D000438:Alcohols / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003864:Depression, Chemical; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000378:metabolism; D005263:Femoral Artery; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006452:Hemoglobinometry; D009206:Myocardium / Q000378:metabolism; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D011651:Pulmonary Artery; D012119:Respiration / Q000187:drug effects; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000494:pharmacology*
D000438:Alcohols; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D013566:Sympathomimetics; D010100:Oxygen